BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors

BACKGROUND: Mismatch repair deficiency (dMMR) is a well-recognized biomarker for response to immune checkpoint blockade (ICB). Strategies to convert MMR-proficient (pMMR) to dMMR phenotype with the goal of sensitizing tumors to ICB are highly sought. The combination of bromodomain containing 4 (BRD4...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Yu, Yang, Bin, Cui, Yaoyuan, Hu, Xingyuan, Li, Xi, Lu, Funian, Qin, Tianyu, Zhang, Li, Hu, Zhe, Guo, Ensong, Fan, Junpeng, Xiao, Rourou, Li, Wenting, Qin, Xu, Hu, Dianxing, Peng, Wenju, Liu, Jingbo, Wang, Beibei, Mills, Gordon B, Chen, Gang, Sun, Chaoyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124306/
https://www.ncbi.nlm.nih.gov/pubmed/37072347
http://dx.doi.org/10.1136/jitc-2022-006070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124306/
https://www.ncbi.nlm.nih.gov/pubmed/37072347
http://dx.doi.org/10.1136/jitc-2022-006070

Ejemplares similares